[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339367-105":59,"doc-detail-339367-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","car-t-therapies-in-multiple-myeloma-unleashing-the-future","CAR T therapies in multiple myeloma - unleashing the future","","Advances in cancer care have elevated treatment outcomes for patients, yet multiple myeloma remains largely incurable, especially among high-risk groups. CAR T-cell therapy has emerged as a transformative immunotherapeutic strategy, using engineered T cells to recognize myeloma-associated targets and deliver potent anti-tumor activity. This review describes the history and functional architecture of CAR T cells, discusses ongoing preclinical and clinical efforts to improve antigen targeting and therapeutic potency, and evaluates current limitations and combination strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-therapies-in-multiple-myeloma-unleashing-the-future/339367/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-therapies-in-multiple-myeloma-unleashing-the-future/339367.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CAR T-cell therapy and why is it important for multiple myeloma?","Question",{"text":112,"@type":113},"CAR T-cell therapy uses engineered chimeric antigen receptors to target specific antigens on cell surfaces. It offers a promising immunotherapy route for multiple myeloma, especially as the disease remains mostly incurable for many patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What basic components make up CAR T cells?",{"text":117,"@type":113},"CARs are fusion proteins with extracellular, transmembrane, and intracellular domains. The intracellular part drives the functional signaling needed for anti-tumor activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What progress and challenges are discussed for CAR T therapies in this field?",{"text":121,"@type":113},"The review highlights FDA approvals and ongoing trials exploring targeting of myeloma-cell antigens, including combination approaches. It also emphasizes that limitations and obstacles still exist, motivating strategies to enhance efficacy and manage side effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339367,1790117352,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Cancer Gene [Therapy](Therapy www.nature.com/cgt)[ www.nature.com/cgt](Therapy www.nature.com/cgt)  \nREVIEW ARTICLE OPEN   \nCAR T therapies in multiple myeloma: unleashing the future  \nMohsen Sheykhhasan 1, Amirhossein Ahmadieh-Yazdi 1,2, Rosario Vicidomini 3,11, Naresh Poondla4,11, Hamid Tanzadehpanah5, Ashkan Dirbaziyan6, Hanie Mahaki7, Hamed Manoochehri 8, Naser Kalhor9 and Paola Dama 10 ✉  \n© The Author(s) 2024  \n\n| | In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that have revolutionized the landscape of care for cancer patients. While traditional pillars such as surgery, chemotherapy, and radiation therapy have long been available, a cutting-edge therapeutic approach called CAR T-cell therapy has emerged as a game-changer in treating multiple myeloma (MM) . This novel treatment method complements options like autologous stem cell transplants and immunomodulatory medications, such as proteasome inhibitors, by utilizing protein complexes or anti-CD38 antibodies with potent complement-dependent cytotoxic effects. Despite the challenges and obstacles associated with these treatments, the recent approval of the second FDA multiple myeloma CAR T-cell therapy has sparked immense promise in the field. Thus far, the results indicate its potential as a highly effective therapeutic solution. Moreover, ongoing preclinical and clinical trials are exploring the capabilities of CAR T-cells in targeting specific antigens on myeloma cells, offering hope for patients with relapsed/refractory MM (RRMM) . These advancements have shown the potential for CAR T cell-based medicines or combination therapies to elicit greater treatment responses and minimize side effects. In this context, it is crucial to delve into the history and functions of CAR T-cells while acknowledging their limitations. We can strategize and develop innovative approaches to overcome these barriers by understanding their challenges. This article aims to provide insights into the application of CAR T-cells in treating MM, shedding light on their potential, limitations, | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  | |\n|  |  |  |\n| | and strategies employed to enhance their efficacy. | |\n|  | Cancer Gene Therapy (2024) 31:667–686; [https://doi.org/10.1038/s41417-024-00750-2](https://doi.org/10.1038/s41417-024-00750-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nMultiple myeloma (MM) is the second most common hematological cancer, characterized by the abnormal proliferation of plasma cells and contributes to 2% of cancer-related deaths in the United States [1]. Initially addressed with melphalan, advances in disease understanding have transformed the therapeutic landscape. The introduction of immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), histone deacetylase inhibitors, and FDA-approved monoclonal antibodies (daratumumab and elotuzumab), has broadened treatment options for MM patients [2–4]. Despite these advancements, multiple myeloma remains predominantly incurable, especially for high-risk patients who do not benefit from the current treatment options [4]. In this context, immunotherapy-based medications present promising advancements in the treatment of multiple myeloma, encompassing checkpoint inhibitors, antibodydrug conjugates, bispecific T cell engagers (BiTEs), and adoptive T cell therapy (ACT) [5–9]. A particularly promising immunotherapeutic avenue is Chimeric Antigen Receptor (CAR) T-cell therapy, which has shown remarkable results in B-cell malignancies [10, 11] FDAapproved CAR T-cell therapies, such as tisagenelcleucel/Kymriah  \n(Novartis) and Brexucabtagene Autoleucel/Tecartus (Kite Pharma) for acute lymphoblastic leukemia (ALL), axicabtagene ciloleucel/Yescarta (Gilead/Kite) and lisocabtagene maraleucel/Breyanzi (Bristol Myers Squibb), and Idecabtagene","cbCaiaY5kVjEUCZZ","https://ap.wps.com/l/cbCaiaY5kVjEUCZZ","pdf",3144594,"English","# Introduction\n# CAR T-cell therapy","[{\"question\":\"What is CAR T-cell therapy and why is it important for multiple myeloma?\",\"answer\":\"CAR T-cell therapy uses engineered chimeric antigen receptors to target specific antigens on cell surfaces. It offers a promising immunotherapy route for multiple myeloma, especially as the disease remains mostly incurable for many patients.\"},{\"question\":\"What basic components make up CAR T cells?\",\"answer\":\"CARs are fusion proteins with extracellular, transmembrane, and intracellular domains. The intracellular part drives the functional signaling needed for anti-tumor activity.\"},{\"question\":\"What progress and challenges are discussed for CAR T therapies in this field?\",\"answer\":\"The review highlights FDA approvals and ongoing trials exploring targeting of myeloma-cell antigens, including combination approaches. It also emphasizes that limitations and obstacles still exist, motivating strategies to enhance efficacy and manage side effects.\"}]","CAR T therapies in multiple myeloma - unleashing the future | PDF",1790029837]